Ensol Biosciences (XKRX:140610) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences ROE % Adjusted to Book Value?

Ensol Biosciences's ROE % for the quarter that ended in Dec. 2024 was 0.00%. Ensol Biosciences's PB Ratio for the quarter that ended in Dec. 2024 was N/A. Ensol Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.

Ensol Biosciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Ensol Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences ROE % Adjusted to Book Value Chart

Ensol Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Ensol Biosciences's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Ensol Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensol Biosciences's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Ensol Biosciences ROE % Adjusted to Book Value Calculation

Ensol Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Ensol Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Ensol Biosciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines